

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
November 7, 2012
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, November 7, 2012.

2. Welcome

Deborah Tapley, R.Ph., called the meeting to order and welcomed members, guests, and staff members.

Ms. Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Deborah Tapley, R.Ph.
Jony Bollinger, MD
James Lindsey, MD

Thomas Phillips, R.Ph.
Gregory Browning, MD
Ed Vess, MD

Tan Platt, MD
Edward Behling, MD

SC DHHS Staff:

Jim Assey, R.Ph.
Janet Giles

Magellan Medicaid Administration:

Lisa Correll, PharmD

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, August 1, 2012.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Pfizer	Deborah Leverette, MD, PA	Pfizer®
Vertex Pharmaceuticals	Michelle Mattox, PharmD	incevik™

Note: Neither speaker addressed the Committee. Dr. Leverette was absent. Dr. Mattox gave her time back to the Committee.

C. Drug Classes for Review

Lisa Correll led the discussion for the following drug classes:

- Antidepressants, Other
- Topical Steroids (Very High)
- Topical Steroids (Medium)
- Ophthalmics for Allergic Conjunctivitis
- Hepatitis C Agents†

†This class was not reviewed. Presented to clarify that Ribavirin generic is to remain PREFERRED.

The chart below represents the recommendations from the P & T Committee:

ANTIDEPRESSANTS, OTHER	
Preferred	Non-Preferred
Bupropion	Venlafaxine ER tabs
Bupropion SR	Pristiq® †
Bupropion XL	
Mirtazapine	
Nefazodone	
Phenelzine	
Trazodone	
Venlafaxine / Venlafaxine ER caps	† Approve with 90 day lookback and diagnosis of Major Depressive Disorder

TOPICAL STEROIDS (VERY HIGH)	
Preferred	Non-Preferred
Betamethasone Dipropionate	Clobetasol Prop Foam
Clobetasol (cream/gel/ointment/solution)	Clobetasol Shampoo / Lotion
Clobetasol Emollient	
Halobetasol Propionate	

TOPICAL STEROIDS (MEDIUM)	
Preferred	Non-Preferred
Betamethasone Valerate (cream/lotion)	Hydrocortisone Valerate (ointment)
Beta-Val (cream/lotion)	Fluticasone Prop (cream/ointment)
Hydrocortisone Butyrate (ointment/solution)	Hydrocort Butyrate (cream)
Hydrocortisone Valerate (cream/solution)	Cloderm
Mometasone Furoate	Fluocinolone Acet (cream/ointment/solution)

OPHTHALMICS for ALLERGIC CONJUNCTIVITIS	
Preferred	Non-Preferred
Alaway® OTC	Patanol®
Elestat®	
Ketotifen OTC	
Pataday®	
Zaditor® OTC	

HEPATITIS C AGENTS†	
Preferred	Non-Preferred
Incivek™	
Pegasys® & Conv Pack	
Peg-Intron® & Redipen	
Ribavirin	
Victrelis™	
†Class was not reviewed. Presented to clarify that Ribavirin generic is to remain PREFERRED.	

5. Old Business

Lisa Correll provided data requested by the P&T Committee during the August 2012 meeting.

6. New Business

7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

- Antidepressants, Other
- Topical Steroids (Very High)
- Topical Steroids (Medium)
- Ophthalmics for Allergic Conjunctivitis
- Hepatitis C Agents†

†This class was not reviewed. Presented to clarify that Ribavirin generic is to remain PREFERRED.

8. **Closing Comments**

The next meeting will be held on Wednesday, February 6, 2013, at 4:00 p.m.

9. **Adjournment**

The meeting adjourned at 4:45 p.m.